Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
RESEARCH TOOLSreports
Biodexa Pharmaceuticals (BDRX) Stock Price & Analysis
334 Followers
BDRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.72 - $21.51
Previous Close$0.81
Volume70.60M
Average Volume (3M)2.13M
Market Cap
$4.42M
Enterprise Value-$2.69M
Total Cash (Recent Filing)£6.42M
Total Debt (Recent Filing)£713.00K
Price to Earnings (P/E)N/A
Beta1.08
Next Earnings
Sep 12, 2024EPS Estimate
>-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,764,475
10 Day Avg. Volume112,333
30 Day Avg. Volume2,125,689
Standard Deviation0.26
R-Squared0.09
Alpha-0.13
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)5.97
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside515.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Biodexa Pharmaceuticals News
PremiumCompany Announcements
Biodexa Pharmaceuticals Seals Deal with Emtora Biosciences
PremiumCompany Announcements
Biodexa Pharmaceuticals Reports 2023 Milestones
Ownership Overview
0.00%
Insiders
0.75% Mutual Funds
0.00% Other Institutional Investors
99.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BDRX FAQ
What was Biodexa Pharmaceuticals’s price range in the past 12 months?
Biodexa Pharmaceuticals lowest stock price was $0.72 and its highest was $21.51 in the past 12 months.
What is Biodexa Pharmaceuticals’s market cap?
Currently, no data Available
When is Biodexa Pharmaceuticals’s upcoming earnings report date?
Biodexa Pharmaceuticals’s upcoming earnings report date is Sep 12, 2024 which is in 138 days.
How were Biodexa Pharmaceuticals’s earnings last quarter?
Biodexa Pharmaceuticals released its earnings results on Apr 19, 2024. The company reported -$0.002 earnings per share for the quarter, the consensus estimate of -$0.002 by $0.
Is Biodexa Pharmaceuticals overvalued?
According to Wall Street analysts Biodexa Pharmaceuticals’s price is currently Undervalued.
Does Biodexa Pharmaceuticals pay dividends?
Biodexa Pharmaceuticals does not currently pay dividends.
What is Biodexa Pharmaceuticals’s EPS estimate?
Biodexa Pharmaceuticals’s EPS estimate is >-$0.01.
How many shares outstanding does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals has 262,207 shares outstanding.
What happened to Biodexa Pharmaceuticals’s price movement after its last earnings report?
Biodexa Pharmaceuticals reported an EPS of -$0.002 in its last earnings report, expectations of -$0.002. Following the earnings report the stock price went down -8.537%.
Which hedge fund is a major shareholder of Biodexa Pharmaceuticals?
Currently, no hedge funds are holding shares in BDRX
---
Biodexa Pharmaceuticals Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (515.38% Upside)
$8.00 (515.38% Upside)
Blogger Sentiment
Bearish
BDRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 11.3%
Last 30 Days ▲ 11.3%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-96.23%
12-Months-Change
Fundamentals
Return on Equity
-180.18%
Trailing 12-Months
Asset Growth
102.21%
Trailing 12-Months
Company Description
Biodexa Pharmaceuticals
Midatech Pharma PLC is a part of the healthcare sector. As a pharmaceutical company, it focuses on commercializing and developing products in oncology and other therapeutic areas. The company has only one operating segment Pipeline Research and Development. The research and development activities involve the discovery and development of pharmaceutical products in the field of nanomedicine and sustained release technology.
---
BDRX Stock 12 Months Forecast
Average Price Target
$8.00
▲(515.38% Upside)
Technical Analysis
Best Analysts Covering BDRX
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-42.30%
initiated a buy rating 3 months ago
Copying Aydin Huseynov's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -42.30% per trade.
---